Publications [#65211] of Michael R. Zalutsky

Papers Published

1. Akabani, G. and Cokgor, I. and Coleman, R.E. and Trotter, D.G. and Wong, T.Z. and Friedman, H.S. and Friedman, A.H. and Garcia-Turner, A. and Herndon, J.E., II. and Delong, D. and McLendon, R.E. and Xiao-Guang Zhao and Pegram, C.N. and Provenzale, J.M. and Bigner, D.D. and Zalutsky, M.R., Dosimetry and dose-response relationships in newly diagnosed patients with malignant gliomas treated with iodine-131-labeled anti-tenascin monoclonal antibody 81C6 therapy, Int. J. Radiat. Oncol. Biol. Phys. (USA), vol. 46 no. 4 (2000), pp. 947 - 58 [S0360-3016(99)00500-3]
   (last updated on 2007/04/15)

   Abstract:
   The objective of this study was to perform the dosimetry and evaluate the dose-response relationships in newly diagnosed patients with malignant brain tumors treated by direct injections of ¹³¹I-labeled 81C6 monoclonal antibody (MAb) into surgically created resection cavities. Absorbed doses to the 2-cm-thick shell as measured from the margins of the resection cavity interface were estimated for 42 patients with primary brain tumors. MR images were used to assess the enhanced-rim volume as a function of time after radiolabeled MAb therapy. Biopsy samples were obtained from 15 patients and 1 autopsy. The average absorbed dose [range] to the 2-cm shell region was 32 [3-59] Gy. For the endpoint of minimal time to MR contrast enhancement, the optimal absorbed dose and initial dose-rate were 43±16 Gy and 0.41±0.10 Gy/h, respectively. There was a correlation between the absorbed dose and dose rate to the shell region and biopsy outcome. In this Phase I study, the maximum tolerated dose (MTD) was 120 mCi. At this MTD, the estimated average absorbed dose and initial dose rate to the 2-cm shell were 41 [9-89] Gy and 0.51 [0.24-1.13] Gy/h, respectively. These values are in agreement with the optimal values based on the time to MR lesion rim enhancement. The average absorbed dose to the 2-cm shell region varied considerably and mainly depended on cavity volume

   Keywords:
   brain;dosimetry;radiation therapy;tumours;